[PDF][PDF] The role of the fallopian tube in ovarian cancer
AA Tone, S Salvador, SJ Finlayson… - Clin Adv Hematol …, 2012 - researchgate.net
High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian
cancer. Research over the past decade has strongly suggested that “ovarian” HGSC arises …
cancer. Research over the past decade has strongly suggested that “ovarian” HGSC arises …
[HTML][HTML] Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Background Granulosa-cell tumors (GCTs) are the most common type of malignant ovarian
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
sex cord–stromal tumor (SCST). The pathogenesis of these tumors is unknown. Moreover …
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
EA Eisenhauer, WW ten Bokkel Huinink… - Journal of clinical …, 1994 - ascopubs.org
PURPOSE Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer
agent with activity in a number of human tumors, including epithelial ovarian cancer. In …
agent with activity in a number of human tumors, including epithelial ovarian cancer. In …
Differences in tumor type in low-stage versus high-stage ovarian carcinomas
Although there are recognized differences in the type of ovarian carcinomas between those
tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of …
tumors diagnosed at low versus high stage, there is a lack of data on stage distribution of …
Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention
Objective The purpose of this study was to assess the uptake and perioperative safety of
bilateral salpingectomy (BS) as an ovarian cancer risk-reduction strategy in low-risk women …
bilateral salpingectomy (BS) as an ovarian cancer risk-reduction strategy in low-risk women …
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study
PJ Hoskins, KD Swenerton, JA Pike, F Wong… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: To evaluate the efficacy of carboplatin plus paclitaxel in primarily advanced or
recurrent endometrial cancers. PATIENTS AND METHODS: Four distinct patient groups …
recurrent endometrial cancers. PATIENTS AND METHODS: Four distinct patient groups …
Prognostic factors in metastatic breast cancer treated with combination chemotherapy
KD Swenerton, SS Legha, T Smith, GN Hortobagyi… - Cancer Research, 1979 - AACR
Six hundred nineteen patients with metastatic breast cancer, treated with a combination of 5-
fluorouracil, Adriamycin, and cyclophosphamide, or close variations of this program, with or …
fluorouracil, Adriamycin, and cyclophosphamide, or close variations of this program, with or …
[HTML][HTML] HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
Background The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …
Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications
OBJECTIVE: An ability to predict survival is of crucial importance in determining the need for
cancer therapy. Recent advances in tumor typing of ovarian carcinomas lead to a …
cancer therapy. Recent advances in tumor typing of ovarian carcinomas lead to a …
[PDF][PDF] Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation
Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia,
Canada, With Evidence for a Survival Bene Page 1 Low-Stage Ovarian Clear Cell Carcinoma …
Canada, With Evidence for a Survival Bene Page 1 Low-Stage Ovarian Clear Cell Carcinoma …